CXCR4 and neoplasm: Anti-CXCR4 treatment-induced vascular normalization and reduced hypoxia could reprogram the tumor immune microenvironment [33] and synergize with the direct effects of AMD3100 on immunosuppressive myeloid and regulatory T cells [34,35].